MXPA03011451A - Formulacion pediatrica de gatifloxacina. - Google Patents
Formulacion pediatrica de gatifloxacina.Info
- Publication number
- MXPA03011451A MXPA03011451A MXPA03011451A MXPA03011451A MXPA03011451A MX PA03011451 A MXPA03011451 A MX PA03011451A MX PA03011451 A MXPA03011451 A MX PA03011451A MX PA03011451 A MXPA03011451 A MX PA03011451A MX PA03011451 A MXPA03011451 A MX PA03011451A
- Authority
- MX
- Mexico
- Prior art keywords
- gatifloxacin
- taste
- found
- masked
- crystalline
- Prior art date
Links
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 title abstract 6
- 229960003923 gatifloxacin Drugs 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 abstract 2
- 239000002244 precipitate Substances 0.000 abstract 2
- 235000021314 Palmitic acid Nutrition 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 235000019658 bitter taste Nutrition 0.000 abstract 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229940072132 quinolone antibacterials Drugs 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 235000019640 taste Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Seasonings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporciona de acuerdo con la presente invencion, la gatifloxacina antibacteriana de quinolona encubierta adecuadamente en el sabor de modo que la misma pueda ser utilizada para formulaciones pediatricas. Un co-precipitado cristalino de gatifloxacina y uno o ambos del acido estearico y acido palmitico en una relacion en peso estrecha se ha encontrado que encubre de manera efectiva el sabor amargo de la gatifloxacina. El sabor de la gatifloxacina es encubierto efectivamente en la boca y en la suspension acuosa a traves de un ciclo de dosificacion total, tipicamente de catorce dias. La gatifloxacina en los co-precipitados cristalinos objetivo se ha encontrado que va a estar facilmente disponible para la absorcion desde el estomago.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29962501P | 2001-06-20 | 2001-06-20 | |
| PCT/US2002/014596 WO2003000175A2 (en) | 2001-06-20 | 2002-05-10 | Pediatric formulation of gatifloxacin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03011451A true MXPA03011451A (es) | 2004-04-05 |
Family
ID=23155586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03011451A MXPA03011451A (es) | 2001-06-20 | 2002-05-10 | Formulacion pediatrica de gatifloxacina. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6589955B2 (es) |
| EP (1) | EP1406572A4 (es) |
| JP (1) | JP4617475B2 (es) |
| KR (1) | KR100888519B1 (es) |
| CN (1) | CN1264514C (es) |
| AR (1) | AR034483A1 (es) |
| AU (1) | AU2002345534B2 (es) |
| BG (1) | BG108444A (es) |
| BR (1) | BR0209692A (es) |
| CA (1) | CA2450742A1 (es) |
| CZ (1) | CZ20033487A3 (es) |
| EE (1) | EE200400018A (es) |
| GE (1) | GEP20053610B (es) |
| HR (1) | HRP20031027A2 (es) |
| HU (1) | HUP0401497A2 (es) |
| IL (1) | IL158863A0 (es) |
| IS (1) | IS7048A (es) |
| MX (1) | MXPA03011451A (es) |
| NO (1) | NO20035605D0 (es) |
| NZ (1) | NZ529611A (es) |
| PE (1) | PE20030126A1 (es) |
| PL (1) | PL366559A1 (es) |
| RU (1) | RU2288218C2 (es) |
| SK (1) | SK14152003A3 (es) |
| TW (1) | TWI224004B (es) |
| UA (1) | UA75656C2 (es) |
| WO (1) | WO2003000175A2 (es) |
| YU (1) | YU100303A (es) |
| ZA (1) | ZA200309173B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1758557B1 (en) | 2004-05-11 | 2011-07-13 | Egalet Ltd. | Swellable dosage form comprising gellan gum |
| US8546423B2 (en) * | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) * | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20070051418A1 (en) * | 2005-09-02 | 2007-03-08 | Rowles Brian A | Multilayer tubes |
| TW201010708A (en) | 2008-06-02 | 2010-03-16 | Intervet Int Bv | Composition comprising an antibiotic and a corticosteroid |
| WO2010042549A1 (en) | 2008-10-07 | 2010-04-15 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
| NZ592717A (en) | 2008-10-07 | 2013-03-28 | Mpex Pharmaceuticals Inc | Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation |
| ES2739979T3 (es) | 2009-09-04 | 2020-02-05 | Horizon Orphan Llc | Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística |
| CN102397546A (zh) * | 2010-09-10 | 2012-04-04 | 广州自远生物科技有限公司 | 一种用于嗅觉或味觉敏感型动物的药物给药方法 |
| CN102397552B (zh) * | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
| WO2018129079A1 (en) * | 2017-01-03 | 2018-07-12 | Thermolife International, Llc | Method of isolating theacrine and composition comprising theacrine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO88836A2 (ro) | 1983-10-11 | 1986-03-31 | Institutul Pentru Controlul De Stat Al Medicamentului Si Cercetari Farmaceutice,Ro | Procedeu de obtinere a comprimatelor cu eritromicina propionat de uz pediatric |
| JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
| NL193682C (nl) | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| US5405617A (en) | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
| IT1255792B (it) | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
| US5407921A (en) | 1993-07-01 | 1995-04-18 | Kao Corporation | Method for suppressing bitter taste |
| JP3449658B2 (ja) | 1994-12-21 | 2003-09-22 | 杏林製薬株式会社 | 安定性に優れた８−アルコキシキノロンカルボン酸水和物並びにその製造方法 |
| DE19633480A1 (de) | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
| US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| CA2227314A1 (en) | 1997-01-24 | 1998-07-24 | Hoechst Aktiengesellschaft | Preparation of concealed taste preparations of antibacterially active quinolone derivatives |
| GB9702799D0 (en) | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| CZ302919B6 (cs) | 1999-07-14 | 2012-01-18 | Schering-Plough Ltd. | Vodný farmaceutický prostredek |
-
2002
- 2002-05-09 US US10/143,487 patent/US6589955B2/en not_active Expired - Lifetime
- 2002-05-10 AU AU2002345534A patent/AU2002345534B2/en not_active Ceased
- 2002-05-10 EE EEP200400018A patent/EE200400018A/xx unknown
- 2002-05-10 CA CA002450742A patent/CA2450742A1/en not_active Abandoned
- 2002-05-10 CN CNB02812409XA patent/CN1264514C/zh not_active Expired - Fee Related
- 2002-05-10 YU YU100303A patent/YU100303A/sh unknown
- 2002-05-10 IL IL15886302A patent/IL158863A0/xx unknown
- 2002-05-10 JP JP2003506621A patent/JP4617475B2/ja not_active Expired - Fee Related
- 2002-05-10 HU HU0401497A patent/HUP0401497A2/hu unknown
- 2002-05-10 NZ NZ529611A patent/NZ529611A/en unknown
- 2002-05-10 PL PL02366559A patent/PL366559A1/xx not_active Application Discontinuation
- 2002-05-10 CZ CZ20033487A patent/CZ20033487A3/cs unknown
- 2002-05-10 GE GE5383A patent/GEP20053610B/en unknown
- 2002-05-10 SK SK1415-2003A patent/SK14152003A3/sk unknown
- 2002-05-10 MX MXPA03011451A patent/MXPA03011451A/es active IP Right Grant
- 2002-05-10 KR KR1020037016647A patent/KR100888519B1/ko not_active IP Right Cessation
- 2002-05-10 EP EP02744141A patent/EP1406572A4/en not_active Withdrawn
- 2002-05-10 BR BR0209692-7A patent/BR0209692A/pt not_active IP Right Cessation
- 2002-05-10 RU RU2003136068/04A patent/RU2288218C2/ru not_active IP Right Cessation
- 2002-05-10 WO PCT/US2002/014596 patent/WO2003000175A2/en not_active Application Discontinuation
- 2002-06-13 AR ARP020102227A patent/AR034483A1/es not_active Application Discontinuation
- 2002-06-14 TW TW091113074A patent/TWI224004B/zh not_active IP Right Cessation
- 2002-06-18 PE PE2002000518A patent/PE20030126A1/es not_active Application Discontinuation
- 2002-10-05 UA UA20031211971A patent/UA75656C2/uk unknown
-
2003
- 2003-11-20 IS IS7048A patent/IS7048A/is unknown
- 2003-11-25 ZA ZA200309173A patent/ZA200309173B/en unknown
- 2003-12-10 HR HR20031027A patent/HRP20031027A2/hr not_active Application Discontinuation
- 2003-12-12 BG BG108444A patent/BG108444A/xx unknown
- 2003-12-16 NO NO20035605A patent/NO20035605D0/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108444A (en) | Pediatric formulation of gatifloxacin | |
| CA2478411C (en) | Palatable oral suspension and method | |
| IL164108A (en) | Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders | |
| EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
| HUP0000450A2 (hu) | 7-(2-Oxa-5,8-diazabiciklo[4.3.0]non-8-il)-kinolon-karbonsav és -naftiridon-karbonsav-származékok alkalmazása Helicobacter pylori fertőzések, és az ezzel kapcsolatos gyomor-bél megbetegedések gyógyítására szolgáló gyógyszerkészítmények előállítására | |
| DE60128258D1 (de) | Indanylderivate zur Behandlung von Atemwegserkrankungen | |
| CA2417106A1 (en) | Piperazine derivatives | |
| EP1443928A4 (en) | TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER IN THE BRAIN | |
| ES2187300A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
| IL167250A (en) | Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases | |
| DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| MXPA05010161A (es) | Combinacion sinergistica que comprende roflumilast y un agente anticolinergico seleccionado a partir de sales de ipratropio, oxitropio y tiotropio para el tratamiento de enfermedades respiratorias. | |
| EP2047854A1 (en) | Pharmaceutical formulations containing ferrous bisglycinate chelate in combination with sweeteners (acesulfam K, sucralose, sorbitol) for improved palatability | |
| UY27339A1 (es) | Formulación pediátrica de gatifloxacina | |
| CA2436537A1 (en) | Pharmaceutical compositions comprising tiotropium salts and antihistamines | |
| IL148739A0 (en) | 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use | |
| NO20014061D0 (no) | Krystallmodifikasjon C av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo-(4.3.0/-nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-kinolinkarboksylsyre | |
| ATE248162T1 (de) | Quinolincarbonsäure-derivate oder salze davon | |
| JP2003342186A (ja) | 鼻炎用内服液剤組成物 | |
| RU2002102491A (ru) | Производные хинолинкарбоновой кислоты или их соли | |
| AU2003255111A8 (en) | The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
| PH12018502650A1 (en) | A buffer free, acid stable low dose volume rotavirus vaccine | |
| KR100408626B1 (en) | Pharmaceutical composition for inhibiting the activity of phosphodiesterase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |